Click here, to read this recommendation in PLAIN language.

Higher risk groups

Some high-risk survivors, for example some CNS tumour survivors, have a greater risk of being affected in different areas simultaneously, such as in their physical health, mental health, social skills, activities of daily living, school or work. A comprehensive approach should be used to identify and address these problems.

In addition, survivors treated with allogeneic HSCT and their HCPs should be aware of the risk of chronic GvHD, which may affect any organ system, especially the skin, mouth, eyes, liver, lungs, gastro-intestinal tract, joints and muscles.

It should be noted that greater caution for late effects is warranted in those survivors who have suffered significant acute toxicity during treatment.

Sometimes, supportive treatment may contribute to long-term adverse effects (for example, increased risk of non-melanoma skin cancer after prolonged voriconazole treatment, or renal toxicity after aminoglycoside use).

Survivors with, or with a suspicion of, a hereditary cancer syndrome should receive additional consultation by a clinical geneticist to determine individualised surveillance methods and frequency based on current available knowledge.

Disclaimer

While PanCare strives to provide accurate and complete information that is up-to-date as of the date of publication, we acknowledge that the sequence of referral and diagnostic tests might vary according to the local and national healthcare system logistics.

It is recognised that survivors and their healthcare professionals have the final responsibility for making decisions concerning their long-term follow-up care. As such, they may choose to either adopt these recommendations or not to do so after individual informed discussion. It is good practice to document this decision.

In addition to regular surveillance, real-time awareness and prompt reporting of new symptoms and signs is essential to the early detection and timely treatment of late effects.

No warranty or representation, expressed or implied, is made concerning the accuracy, reliability, completeness, relevance, or timeliness of this information.

The PanCare materials are free to use for anyone aiming to inform about late effects and long-term survivorship care. However, no financial advantage may be achieved. All communication should reference PanCare and link to the PanCare website.